This is a working overview of visceral adipose tissue, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-06 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
纯度与身份确认依赖色谱与质谱的组合。反相高效液相色谱在 214 nm 紫外检测下分离主峰与相关杂质，给出纯度百分比与保留时间；电喷雾或基质辅助激光解吸电离质谱提供分子量，用于确认 N 端修饰是否完整。序列层面可通过肽图或氨基酸分析验证。含量测定常用紫外吸收法或氮元素分析，不同方法之间需要做交叉校验。
冻干粉末一般在 -20°C 或更低温度、干燥避光条件下保存，可维持较长时间的稳定。复溶后稳定性明显下降，溶液中的肽链易发生水解、氧化与聚集，通常需冷藏并在短期内用完。反复冻融会加速聚集与降解，建议分装后单次使用。缓冲体系的 pH 与离子强度同样影响聚集速率，需要按具体实验条件验证。
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
=== Contact inhibition of locomotion === Contact inhibition of locomotion (CIL) is a process in which the cell changes its direction of movement after colliding into another cell. Those cells could be of the same cell type or different types. The contacts (cell-junctions) are created by transmembrane glycoproteins named cadherins (E-cadherin, N-cadherin or cadherin 11) and other proteins. After cell-cell contact, the protrusions of cells in the contact direction are inhibited. In the CIL process, cells migrate away from each other by repolarizing in the new direction, so that new protrusions are formed in the front while contractions pull the back from contact.
==== Diverse food sourcing ==== Diverse sourcing of food, such as through international trade, is a key strategy for building agrifood systems' resilience because it buffers the food supply against shocks and stresses. The volume of agrifood trade more than doubled between 2000 and 2024. Although international trade buffers against domestic shocks, it increases exposure to external shocks and can itself become a channel of shock transmission, therefore having diverse international trade partners is key. Enhancing diversity in terms of commodities is also essential for ensuring the supply of food necessary for healthy diets. However, evidence on the diversity of food supply in terms of domestic production, imports and stocks reveal that the potential of international trade is not equally well exploited in all countries. Low-income countries, such as in sub-Saharan Africa, are among those with the lowest diversity of imports as the food supply is mostly determined by what is produced for the domestic market.
The search for patterns in the variations of birds was attempted by many. Friedrich Wilhelm Joseph Schelling (1775–1854), his student Johann Baptist von Spix (1781–1826), and several others believed that a hidden and innate mathematical order existed in the forms of birds. They believed that a "natural" classification was available and superior to "artificial" ones. A particularly popular idea was the Quinarian system popularised by Nicholas Aylward Vigors (1785–1840), William Sharp Macleay (1792–1865), William Swainson, and others. The idea was that nature followed a "rule of five" with five groups nested hierarchically. Some had attempted a rule of four, but Johann Jakob Kaup (1803–1873) insisted that the number five was special, noting that other natural entities such as the senses also came in fives. He followed this idea and demonstrated his view of the order within the crow family. Where he failed to find five genera, he left a blank insisting that a new genus would be found to fill these gaps. These ideas were replaced by more complex "maps" of affinities in works by Hugh Edwin Strickland and Alfred Russel Wallace. A major advance was made by Max Fürbringer in 1888, who established a comprehensive phylogeny of birds based on anatomy, morphology, distribution, and biology. This was developed further by Hans Gadow and others. The Galapagos finches were especially influential in the development of Charles Darwin's theory of evolution.
Sources: en.wikipedia.org
=== Amateur === Lisa has been weight training since 2003 and has been conditioning for competitive entry since 2008. She first really got into bodybuilding in 2006 while she was living in Japan while she was teaching English. Her boyfriend at the time was a Japanese bodybuilding champion and she started reading up on bodybuilding, such as Negrita Jayde, and started training with weights. In 2007, after she got married, she went to see the 2007 Ms. Olympia competition for their honeymoon and was impressed when she saw female bodybuilders for the first time. Former UK junior champion Lewis Breed oversees her training and pre-contest preparation for bodybuilding. She competed in her debut competition at the 2009 NABBA England, placing second place behind Jennie Ellam. She then competed at the 2009 NABBA Universe achieving second place to Larissa Cunha. Her best win was first place at the UKBFF British Championships, where she won the Ladies Physique class. On 19 March 2014, she announced that she had been awarded her IFBB pro card and can now compete as a pro.
People with irritable bowel syndrome (IBS) typically report that they suffer with abdominal cramps and constipation. In some patients, chronic constipation is interspersed with brief episodes of diarrhoea; while a minority of patients with IBS have only diarrhoea. The presentation of symptoms is usually months or years and commonly patients consult different doctors, without great success, and doing various specialized investigations. It notices a strong correlation of the reported symptoms with stress; indeed diarrhoeal discharges are associated with emotional phenomena. IBS blood is present only if the disease is associated with haemorrhoids. Research conducted on irritable bowel syndrome in the 2000s, faecal incontinence and the gastrointestinal complications of HIV have used the Bristol scale as a diagnostic tool easy to use, even in research which lasted for 77 months. Historically, this scale of assessment of the faeces has been recommended by the consensus group of Kaiser Permanente Medical Care Program (San Diego, California, US) for the collection of data on functional bowel disease (FBD). More recently, according to the latest revision of the Rome III Criteria, six clinical manifestations of IBS can be identified:
prostacyclin synthase to create prostacyclin thromboxane-A synthase to create thromboxane A2 and 12-(S)-hydroxy-5Z,8E,10E-heptadecatrienoic acid (HHT) (see 12-Hydroxyheptadecatrienoic acid) prostaglandin D2 synthase to create prostaglandin D2 prostaglandin E synthase to create prostaglandin E2 prostaglandin F synthase to create prostaglandin F2α It rearranges non-enzymatically to:
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.